Your browser doesn't support javascript.
loading
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang, Qi; Zhang, Jian; Zhong, Haijun; Yuan, Ying; Yang, Lei; Zhang, Qingyuan; Ji, Dongmei; Gong, Jifang; Li, Jing; Yao, Zhenling; Qi, Chuan; Wang, Jianming; Lu, Lingmin; Shi, Michael; Qian, Xueming; Shen, Lin; Li, Jian; Hu, Xichun.
Afiliação
  • Zhang Q; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fucheng Road 52, Haidian District, Beijing, 100142, China.
  • Zhang J; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Zhong H; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Yuan Y; Department of Colorectal Medicine, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Yang L; Department of Medical Oncology, Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhang Q; Department of Oncology, Nantong Tumor Hospital & Affiliated Tumor Hospital of Nantong University, Nantong, China.
  • Ji D; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Gong J; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Li J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Yao Z; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fucheng Road 52, Haidian District, Beijing, 100142, China.
  • Qi C; Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China.
  • Wang J; Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China.
  • Lu L; Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China.
  • Shi M; Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China.
  • Qian X; Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China.
  • Shen L; Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China.
  • Li J; Suzhou Transcenta Therapeutics Co., Ltd, Suzhou, China.
  • Hu X; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fucheng Road 52, Haidian District, Beijing, 100142, China.
Cancer Immunol Immunother ; 72(8): 2729-2739, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37115210
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por Vírus Epstein-Barr / Linfoma / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por Vírus Epstein-Barr / Linfoma / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article